Intravenous Fish Oil in Critically Ill Cardiac Patients
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
A large body of evidence has accumulated showing that n-3 PUFAs exert extensive cardiac
effects. The development of commercial solutions of FO opens perspectives for therapeutic
applications in patients with acute cardiac conditions.the 3 following hypotheses will be
addressed in patients requiring cardiac surgery under cardiopulmonary bypass or after
myocardial infarction:perioperative /post-PTCA intravenous fish oil modifies the composition
of membrane phospholipids in platelets and cardiac cells, blunts the physiological response
to cardiac surgery/myocardial infarction, and reduces the incidence of arrhythmias, and
reduces the occurrence of systolic dysfunction.